CXCL8 and neoplasm: Dual neutralization of IL8/VEGF significantly reduced tumor weight compared with enzalutamide/anti-VEGF (P = 0.011), highlighting the importance of coinhibition of IL8 and VEGF to enhance tumor reduction.